Acumen Pharmaceuticals (ABOS) Corporate presentation summary

Market opportunity and unmet need

• Early Alzheimer's disease represents a significant and expanding market, with over 7 million affected in the U.S. and increasing diagnoses due to improved biomarkers and treatment options.

• Current anti-amyloid therapies are gaining traction, but there is demand for next-generation treatments with improved efficacy, safety, and delivery methods.

Pipeline and clinical development

• Sabirnetug (ACU193) is a monoclonal antibody highly selective for toxic amyloid beta oligomers, showing positive Phase 1 results and ongoing Phase 2 (ALTITUDE-AD) with topline results expected late 2026.

• Subcutaneous formulation of sabirnetug demonstrated favorable pharmacokinetics and safety in healthy volunteers, supporting further development for more convenient dosing.

• Enhanced Brain Delivery (EBD) program leverages transferrin receptor technology to improve brain penetration, with preclinical candidate data expected early 2026 and IND filing targeted for mid-2027.

Clinical data and differentiation

• Phase 1 INTERCEPT-AD study showed sabirnetug achieves dose-proportional target engagement, significant improvements in CSF and plasma biomarkers, and robust amyloid plaque reduction comparable to leading therapies.

• Safety profile is compelling, with low incidence of ARIA-E and no cases in ApoE4 homozygotes, suggesting a broad therapeutic index.

• Sabirnetug demonstrates high selectivity for oligomers over monomers and plaques, potentially reducing off-target effects and improving efficacy.